Understanding how a specific enzyme affects lung cancer and the immune system
Investigating the Role of PFKFB4 in the Immune Regulation of Lung Cancer
This study is looking at how a specific enzyme affects lung cancer and the immune system, and it’s testing a new treatment that might help boost the body's ability to fight the cancer while slowing down its growth, which could lead to better outcomes for patients with non-small cell lung cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10665075 on NIH RePORTER |
What this research studies
This research investigates the role of the enzyme PFKFB4 in the immune regulation of non-small cell lung cancer (NSCLC). The study focuses on how this enzyme influences the metabolism of cancer cells and the activity of immune cells that can either suppress or promote tumor growth. By using a novel small molecule inhibitor called MPN-22, researchers aim to reduce the glycolysis in lung tumors and enhance the immune response against cancer. Patients may benefit from insights into new treatment strategies that could improve outcomes for lung cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer (NSCLC).
Not a fit: Patients with other types of lung cancer or those without lung cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance immune response and reduce tumor growth in lung cancer patients.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting metabolic pathways in cancer treatment.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Telang, Sucheta — University of Louisville
- Study coordinator: Telang, Sucheta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.